Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 31,526,164	$ 44,273,319
Short-term investments	5,147,853	14,239,145
Prepaid expenses and other current assets, including from affiliated entity	3,239,232	2,610,882
Total current assets	39,913,249	61,123,346
Fixed assets, net	1,888,725	2,527,603
Investments in affiliated entity	0	2,103,688
Operating lease right-of-use assets	5,670,451	6,542,923
Other assets	1,917,069	2,012,475
Total assets	49,389,494	74,310,035
Current liabilities:
Accrued clinical trial expenses	338,461	650,680
Common stock warrant liabilities	25,024,799	29,067,162
Operating lease liability	2,898,637	2,822,622
Total current liabilities	39,915,059	43,668,555
Operating lease liability, net of current portion	5,103,352	6,545,204
Total liabilities	45,018,411	50,213,759
Stockholders’ equity:
Preferred stock	0	0
Common stock	82,342	68,997
Additional paid-in capital	1,845,429,136	1,839,830,405
Accumulated deficit	(1,840,860,419)	(1,815,165,163)
Accumulated other comprehensive loss	(279,976)	(637,963)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity	4,371,083	24,096,276
Total liabilities and stockholders’ equity	49,389,494	74,310,035
Nonrelated Party
Current liabilities:
Accounts payable and accrued expenses	11,653,162	11,053,618
Related Party
Current liabilities:
Accounts payable and accrued expenses	$ 0	$ 74,473

Accrued Clinical Trial Expense, Current

No definition available.

Name:	ino_AccruedClinicalTrialExpenseCurrent
Namespace Prefix:	ino_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.